Media Centre
The News Centre is intended to provide resources for media professionals only. It is not intended for use by healthcare professionals, patients or the general public.
To access, please confirm that you are an accredited member of the press.
I hereby confirm that I am an accredited member of the press
Press Releases
29, January, 2021
Johnson & Johnson Announces Single-Shot Janssen COVID-19 Vaccine Candidate Met Primary Endpoints in Interim Analysis of its Phase 3 ENSEMBLE Trial
01, December, 2020
European Commission Authorises Janssen's TREMFYA®▼ (guselkumab), a First-in-Class Treatment for Active Psoriatic Arthritis (PsA)
16, November, 2020
Johnson & Johnson Initiates Second Global Phase 3 Clinical Trial of its Janssen COVID-19 Vaccine Candidate
08, September, 2020
Biopharma Leaders Unite To Stand With Science
Quick Links
FOLLOW US
Janssen UK
@JanssenUK
-
In the UK, around 130 people a day are told they have #LungCancer. That's 130 too many. This #WorldLungCancerDay, i… https://t.co/ibnifoMf9e
1 day 5 hours ago